

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number
WO 02/060339 A2

(51) International Patent Classification⁷: **A61F**

(21) International Application Number: PCT/US02/02011

(22) International Filing Date: 25 January 2002 (25.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/264,957 30 January 2001 (30.01.2001) US

(71) Applicant (*for all designated States except US*): **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **STELMACH, Christine** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(74) Common Representative: **AYLER, Sylvia, A. et al.**; Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/060339 A2

(54) Title: OPTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION

(57) Abstract: This invention relates a formulation comprising potent potassium channel blockers or pharmaceutically acceptable salts thereof in combination with peanut oil for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

TITLE OF THE INVENTION

OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION

BACKGROUND OF THE INVENTION

5 Recently potassium channel blockers were found to reduce intraocular pressure in the eye and therefore provide an approach to the treatment of ocular hypertension and the degenerative ocular conditions related thereto. Blockage of potassium channels can diminish fluid secretion, and under some circumstances, increase smooth muscle contraction and would be expected to lower IOP and have
10 neuroprotective effects in the eye. (see US Patent Nos. 5,573,758 and 5,925,342; Moore, et al., Invest. Ophthalmol. Vis. Sci 38, 1997; WO 89/10757, WO94/28900, and WO 96/33719).


 The present invention relates to potassium channel blocker compositions, and methods of preparation thereof. The composition can be used in
15 the treatment of glaucoma and/or ocular hypertension. The composition provides ease for ocular dosing in solution, and a favorable therapeutic efficacy and duration of action.

 Previously compounds which were insoluble in aqueous vehicles were suspended in hydroxy-cellulose for ocular dosing. The disadvantages of ocular dosing
20 of suspensions is that particle size must be controlled for drug dissolution and for patient comfort, and therapeutic effect is dependent on the dissolution rate of drug particles.


 The instantly claimed invention relates to a composition containing a potassium channel blocker in combination with peanut oil, which allows compounds
25 which are not soluble in aqueous solution to be dosed in solution thereby avoiding the problems associated with ocular dosing of suspensions. See Yamamoto et al., S.T.P. Pharma Sciences 4(2) 133-138, 1994 for a discussion on the use of peanut oil as a vehicle for dosing of insulin suspensions (incorporated herein by reference).

30 SUMMARY OF THE INVENTION

 This invention relates to novel ophthalmic compositions comprising potent potassium channel blockers in combination with peanut oil. This invention also relates to novel ophthalmic compositions comprising potent potassium channel blockers of the structural formulas:



FORMULA I, or



FORMULA II

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof:
wherein,

- 10 R and R^x independently represent C₁₋₆ alkyl, (CH₂)_naryl, (CH₂)_nheteroaryl, (CH₂)_n heterocycloalkyl, said alkyl, aryl or heteroaryl optionally substituted with 1-3 groups of R_Y;

Y represents -(CH₂)_nSCOR^Z;

15

X represents CH₂, or O (in which m does not exist);

R_Y represents hydrogen, C₁₋₆ alkoxy, C₁₋₆ alkyl, CF₃, nitro, amino, cyano, C₁₋₆ alkylamino, or halogen and

20

R^Z represents C₁₋₆ alkoxy, or C₁₋₆ alkyl;

m represents 1-3;

n represents 0-3

R₁ represents hydrogen or C₁₋₆ alkyl;

5

R₂, R_{3a} and R_{3b} independently represent hydrogen, C₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₄₋₁₀ heterocycloalkyl, C₄₋₁₀ heteroaryl, or C₆₋₁₀ aryl;

R₄ represents hydrogen, C₁₋₆ alkoxy, C₁₋₆ alkyl, CF₃, or halogen;

10

R₅ represents hydrogen, C₁₋₆ alkoxy, C₁₋₆ alkyl, CF₃, nitro, amino, cyano, C₁₋₆ alkylamino, or halogen;

R₆ represents hydrogen, halogen or C₁₋₆ alkyl; and

15

R₇ represents H, halo, OH, NO₂, NH₂, CN, alkoxy, -COO-, alkoxycarbonyl, haloalkyl, alkoxycarbonylalkyl, or alkylsulphonyl in combination with peanut oil.

20 This invention further relates to a composition comprising peanut oil in combination with the potassium channel blockers disclosed in Merck & Co., Inc. Attorney Docket number 20798PV under U.S.S.N 60/264,954, filed simultaneously with this application, U.S.S.N. 60/176,695, filed January 18, 2000 and U.S.S.N 60/176,694, filed January 19, 2000 all incorporated herein by reference.

25 The compositions are useful in the treatment of glaucoma and other conditions which are related to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compositions to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

This and other aspects of the invention will be realized upon inspection of the invention as a whole.

30

DETAILED DESCRIPTION OF THE INVENTION

The invention is described herein in detail using the terms defined below unless otherwise specified.

35 The term "alkyl" refers to a monovalent alkane (hydrocarbon) derived radical containing from 1 to 10 carbon atoms unless otherwise defined. It may be

straight, branched or cyclic. Preferred alkyl groups include methyl, ethyl, propyl, isopropyl, butyl, t-butyl, cyclopentyl and cyclohexyl. When the alkyl group is said to be substituted with an alkyl group, this is used interchangeably with "branched alkyl group".

5 Cycloalkyl is a specie of alkyl containing from 3 to 15 carbon atoms, without alternating or resonating double bonds between carbon atoms. It may contain from 1 to 4 rings which are fused.

 Alkoxy refers to C₁-C₆ alkyl-O-, with the alkyl group optionally substituted as described herein.

10 Halogen (halo) refers to chlorine, fluorine, iodine or bromine.

 Aryl refers to aromatic rings e.g., phenyl, substituted phenyl and the like, as well as rings which are fused, e.g., naphthyl, phenanthrenyl and the like. An aryl group thus contains at least one ring having at least 6 atoms, with up to five such rings being present, containing up to 22 atoms therein, with alternating (resonating) double bonds between adjacent carbon atoms or suitable heteroatoms. The preferred aryl groups are phenyl, naphthyl and phenanthrenyl. Aryl groups may likewise be substituted as defined. Preferred substituted aryls include phenyl and naphthyl.

15 The term "heterocycloalkyl" refers to a cycloalkyl group (nonaromatic) in which one of the carbon atoms in the ring is replaced by a heteroatom selected from O, S or N, and in which up to three additional carbon atoms may be replaced by hetero atoms.

 The term "heteroatom" means O, S or N, selected on an independent basis.

25 The term "heteroaryl" refers to a monocyclic aromatic hydrocarbon group having 5 or 6 ring atoms, or a bicyclic aromatic group having 8 to 10 atoms, containing at least one heteroatom, O, S or N, in which a carbon or nitrogen atom is the point of attachment, and in which one or two additional carbon atoms is optionally replaced by a heteroatom selected from O or S, and in which from 1 to 3 additional carbon atoms are optionally replaced by nitrogen heteroatoms, said heteroaryl group being optionally substituted as described herein. Examples of this type are pyrrole, pyridine, oxazole, thiazole and oxazine. Additional nitrogen atoms may be present together with the first nitrogen and oxygen or sulfur, giving, e.g., thiadiazole.

30 One embodiment of this invention is realized when R₂ is C₁₋₆ alkyl or C₃₋₁₀ cycloalkyl and all other variables are as originally described for the compounds of formula I.

Another embodiment of this invention is realized when R_{3b} is C₁₋₆ alkyl or C₃₋₁₀ cycloalkyl and all other variables are as originally described for the compounds of formula I.

5 A preferred embodiment of this invention is realized when R₁ is C₁₋₆ alkyl, R₂ and R_{3b} independently are C₁₋₆ alkyl or C₃₋₁₀ cycloalkyl, R₄ is hydrogen, R₅ is C₁₋₆ alkoxy, C₁₋₆ alkyl, R_{3a} is hydrogen and R₆ is halogen or C₁₋₆ alkyl for the compounds of formula I.

A more preferred embodiment of this invention is realized when R₁ is C₁₋₃ alkyl, R₂ and R_{3b} independently are C₁₋₄ alkyl or C₅₋₁₀ cycloalkyl, R₄ is
10 hydrogen, R₅ is C₁₋₃ alkoxy, and R₆ is halogen for the compounds of formula I.

One embodiment of this invention is realized when R is C₁₋₆ alkyl, or (CH₂)_n aryl, and all other variables are as originally described for the compounds of formula II.

Another embodiment of this invention is realized when R^x is C₁₋₆ alkyl, or (CH₂)_n aryl, and all other variables are as originally described for the
15 compounds of formula II.

Yet another embodiment of this invention is realized when X is CH₂ and all other variables are as originally described for the compounds of formula II.

Still another embodiment of this invention is realized when Y is –
20 (CH₂)_nSCOR^z wherein n=0, and all other variables are as originally described for the compounds of formula II.

Another embodiment of this invention is realized when Y is – (CH₂)_nSCOR^z, wherein n=1-3, and all other variables are as originally described for the compounds of formula II.







25 A preferred embodiment of this invention is realized when R is (CH₂)_n aryl, R^x is C₁₋₆ alkyl, Y is (CH₂)_nSCOR^z, X is CH₂ and m=1 for the compounds of formula II.


Another preferred embodiment of this invention is realized when R is (CH₂)_n aryl, R^x is C₁₋₆ alkyl, Y is (CH₂)_nSCOR^z, X is CH₂ and m=2 for the
30 compounds of formula II.

Still another preferred embodiment of this invention is realized when R is C₁₋₆ alkyl, R^x is (CH₂)_n aryl, Y is (CH₂)_n SCOR^z, X is CH₂ and m=2 for the compounds of formula II.


Yet another preferred embodiment of this invention is realized when R is $(\text{CH}_2)_n$ aryl, R^x is $(\text{CH}_2)_n$ aryl, Y is $(\text{CH}_2)_n$ SCOR^z, X is CH_2 and $m=2$ for the compounds of formula II.

Preferred maxi-K channel blockers of the claimed composition are
5 selected from:






compound 7






compound 8

5



compound 9



This invention is also concerned with compositions comprising other ocular thereapeutic agents such as penitrem-A, paxillene, β -adrenergic blocking agents (betaxolol, bufenolol, carteolol, levobunolol, metipranolol or timolol or a pharmaceutically acceptable salt thereof), parasymphomimetic agents such as pilocarpine, carbonic anhydrase inhibitors (dorzolamide, acetazolamide, metazolamide or brinzolamide or a pharmaceutically acceptable salt thereof), prostaglandin (latanoprost, rescular, S1033 or a hypotensive lipid derived from PGF2 α prostaglandins such as prostamide (AGN 192024)) either alone or in combination thereof along with peanut oil. An example of a hypotensive lipid (the

carboxylic acid group on the α -chain link of the basic prostaglandin structure is replaced with electrochemically neutral substituents) is that in which the carboxylic acid group is replaced with a C₁₋₆ alkoxy group such as OCH₃ (PGF_{2a} 1-OCH₃), or a hydroxy group (PGF_{2a} 1-OH). One or more of these ocular therapeutic agents can be
5 combined with the potassium channel blockers and peanut oil of the claimed composition.

Preferred potassium channel blockers are calcium activated potassium channel blockers. More preferred potassium channel blockers are high conductance, calcium activated potassium (Maxi-K) channel blockers. Maxi-K
10 channels are a family of ion channels that are prevalent in neuronal, smooth muscle and epithelial tissues and which are gated by membrane potential and intracellular Ca²⁺.

Intraocular pressure (IOP) is controlled by aqueous humor dynamics. Aqueous humor is produced at the level of the non-pigmented ciliary epithelium and
15 is cleared primarily via outflow through the trabecular meshwork. Aqueous humor inflow is controlled by ion transport processes. It is thought that maxi-K channels in non-pigmented ciliary epithelial cells indirectly control chloride secretion by two mechanisms; these channels maintain a hyperpolarized membrane potential (interior negative) which provides a driving force for chloride efflux from the cell, and they
20 also provide a counter ion (K⁺) for chloride ion movement. Water moves passively with KCl allowing production of aqueous humor. Inhibition of maxi-K channels in this tissue would diminish inflow. Maxi-K channels have also been shown to control the contractility of certain smooth muscle tissues, and, in some cases, channel blockers can contract quiescent muscle, or increase the myogenic activity of
25 spontaneously active tissue. Contraction of ciliary muscle would open the trabecular meshwork and stimulate aqueous humor outflow, as occurs with pilocarpine. Therefore maxi-K channels could profoundly influence aqueous humor dynamics in several ways; blocking this channel would decrease IOP by affecting inflow or outflow processes or by a combination of affecting both inflow/outflow processes.

30 The present invention is based upon the finding that maxi-K channels, if blocked, inhibit aqueous humor production by inhibiting net solute and H₂O efflux and therefore lower IOP. This finding suggests that maxi-K channel blockers are useful for treating other ophthalmological dysfunctions such as macular edema and macular degeneration. It is known that lowering IOP promotes blood flow to the

retina and optic nerve. Accordingly, the compositions of this invention are useful for treating macular edema and/or macular degeneration.

Macular edema is swelling within the retina within the critically important central visual zone at the posterior pole of the eye. An accumulation of fluid within the retina tends to detach the neural elements from one another and from their local blood supply, creating a dormancy of visual function in the area.

Glaucoma is characterized by progressive atrophy of the optic nerve and is frequently associated with elevated intraocular pressure (IOP). It is possible to treat glaucoma, however, without necessarily affecting IOP by using drugs that impart a neuroprotective effect. See Arch. Ophthalmol. Vol. 112, Jan 1994, pp. 37-44; Investigative Ophthalmol. & Visual Science, 32, 5, April 1991, pp. 1593-99. It is believed that maxi-K channel blockers which lower IOP are useful for providing a neuroprotective effect. They are also believed to be effective for increasing retinal and optic nerve head blood velocity and increasing retinal and optic nerve oxygen by lowering IOP, which when coupled together benefits optic nerve health. As a result, the claimed composition can be useful for increasing retinal and optic nerve head blood velocity, increasing retinal and optic nerve oxygen tension as well as providing a neuroprotective effect or a combination thereof.

The herein examples illustrate but do not limit the claimed invention. The claimed formulations are potassium channel antagonists in combination with peanut oil and are thus useful in the described neurological disorders in which it is desirable to maintain the cell in a depolarized state to achieve maximal neurotransmitter release. The compounds produced in the present invention are readily combined with suitable and known pharmaceutically acceptable excipients to produce compositions which may be administered to mammals, including humans, to achieve effective potassium channel blockage.

The maxi-K channel blocker formulations of the instant invention can be administered in a therapeutically effective amount intravenously, subcutaneously, topically, transdermally, parenterally or any other method known to those skilled in the art. Ophthalmic pharmaceutical compositions are preferably adapted for topical administration to the eye in the form of solutions, suspensions, ointments, creams or as a solid insert.

The novel ophthalmic formulations of this invention comprise from 0.01 to 5% wt./wt. maxi-K channel blocker/peanut oil and especially 0.1 to 2% of medicament in peanut oil. Higher dosages as, for example, about 10% or lower

dosages can be employed provided the dose is effective in reducing intraocular pressure, treating glaucoma, increasing blood flow velocity or oxygen tension. For a single dose, from between 0.001 to 5.0 mg, preferably 0.005 to 2.0 mg, and especially 0.005 to 1.0 mg of the maxi-K channel blocker in peanut oil can be applied to the
5 human eye.

The novel method of this invention comprises the topical ocular administration of about 0.001 to 5 mg per day, preferably about 0.25 to 3 mg per day, of a maxi-K channel blocker contained in peanut oil to each eye.

Regarding combinations, the ophthalmic formulations of the claimed
10 invention will comprise about, for example, 0.05 to 5% (w/w) of a carbonic anhydrase inhibitor or prostaglandin, usually about 0.5 to 3% (w/w) or about 0.01 to 1% (w/w) of β -adrenergic antagonist, preferably about 0.1 to 0.5% (w/w) in combination with the maxi-K channel blocker and peanut oil, which can be administered on a 1 to 2 times a day schedule. Alternatively, the ophthalmic formulation can contain, for
15 example 0.05 to 5% (w/w) of a carbonic anhydrase inhibitor, 0.01 to 1% (w/w) of β -adrenergic antagonist and 0.01 to 5% (w/w) of a maxi-K channel blocker in combination with 0.01 to 5% peanut oil.

The pharmaceutical preparation which contains the compound may be conveniently admixed with other non-toxic pharmaceutical organic carriers, or with
20 other non-toxic pharmaceutical inorganic carrier. Typical of other pharmaceutically acceptable carriers are, for example, water, mixtures of water and water-miscible solvents such as lower alkanols or aralkanols, vegetable oils, polyalkylene glycols, petroleum based jelly, ethyl cellulose, hydroxypropyl cellulose, ethyl oleate, carboxymethyl-cellulose, polyvinylpyrrolidone, isopropyl myristate and other
25 conventionally employed acceptable carriers. The pharmaceutical preparation may also contain non-toxic auxiliary substances such as emulsifying, preserving, wetting agents, bodying agents and the like, as for example, polyethylene glycols 200, 300, 400 and 600, carbowaxes 1,000, 1,500, 4,000, 6,000 and 10,000. The peanut oil vehicle is any preparation containing peanut oil in combination with a maxi-K
30 channel blocker.

Suitable subjects for the administration of the formulation of the present invention include primates, man and other animals, particularly man and domesticated animals such as cats and dogs.

The ophthalmic solution or suspension may be administered as often as necessary to maintain an acceptable IOP level in the eye. It is contemplated that administration to the mamalian eye will be about once or twice daily.

For topical ocular administration the novel formulations of this invention may take the form of solutions, gels, ointments, suspensions or solid inserts, formulated so that a unit dosage comprises a therapeutically effective amount of the active component or some multiple thereof in the case of a combination therapy.

The pharmaceutical preparation may also be in the form of a solid insert such as one which after dispensing the drug remains essentially intact as described in U.S. Patents 4,256,108; 4,160,452; and 4,265,874; or a bio-erodible insert that either is soluble in lacrimal fluids, or otherwise disintegrates as described in U.S. Patent 4,287,175 or EPO publication 0,077,261.

The following examples of ophthalmic formulations, wherein the active ingredient is dissolved in peanut oil are given by way of illustration.

15

SOLUTION COMPOSITIONS

Test	I	II	III	IV	V	VI
Formulation 1						
Compound 3	0.5%	0.2%	0.1%, 0.05%	0.025%	0.01%	
Peanut oil						
Formulation 2						
Timolol-free base	0.5%	0.2%	0.1%, 0.05%	0.025%	0.01%	
Peanut oil						
Formulation 3						
Paxilline	0.5%	0.2%	0.1%, 0.05%	0.025%	0.01%	
Peanut oil						
Formulation 4						
Penitrem A	0.5%	0.2%	0.1%, 0.05%	0.025%	0.01%	
Peanut oil						
Formulation 5						
Compound 2	0.5%	0.2%	0.1%, 0.05%	0.025%	0.01%	
Peanut oil						

Formulation 6

Aflertrem

0.5% 0.2% 0.1%, 0.05% 0.025% 0.01%

Peanut oil

5

The solubility of the formulations are determined using HPLC (Zorbax Rx C8 15 cm x 4.6 mm column; 85% acetonitrile/15% 0.1% triethyl ammonium acetate, pH 6.3; flow rate 1 mL/min; wavelength 265 nm; run time 12 minutes).

10

EXAMPLE 1

Intraocular pressure measurements (IOP) were performed in conscious adult, pigmented Dutch Belted rabbits (2-4 kg). The animals were allowed free access to standard laboratory diet and tap water, and were housed on a 12 hour light/dark cycle. Seven day rest or washout periods were allowed between assessment of the effects of topically administered treatments on IOP. In order to measure IOP, rabbits were placed in commercially available restraint boxes. Rabbits were conditioned to the restraint boxes on at least two occasions for a period of time ranging up to 6 hours before their first study. On the morning of each experiment, rabbits were placed in restraint boxes for a period of one hour before the first measurement of IOP. IOP was recorded using a pneumatic tonometer (Alcon Applanation Pneumatograph). Eyelids were gently separated manually and the fingers of the operator were held far enough from the eye to avoid any direct pressure on the eye and surrounding tissues. The membrane of the tonometer was placed on the central part of the cornea. Each measure of IOP lasted 3-5 seconds during which time the animal was completely relaxed. In general, two measures for each eye was sufficient, the first measure being frequently discarded. The tonometer tracing represents the oscillations which correspond to ocular pulsations; the average value of the oscillations corresponded to the level of IOP in mm Hg.

30

The initial measurement of control IOP was done on a number of rabbits, and 12 rabbits whose control IOP were between 17-25 mm Hg (values of IOP considered to be normal) were selected for study. In each study, the rabbits were separated into two equal subgroups of 6 rabbits each with essentially equivalent control IOPs. Each study consisted of the topical administration of active test substance to one subgroup of 6 rabbits (12 eyes) and vehicle to one subgroup of 6

35

rabbits (12 eyes); total number of eyes tested per study being 24. In each study, one drop (volume of 50 μ l) of active test substance per vehicle was instilled by means of a Hamilton syringe into both eyes of each rabbit at time) (T_0). IOPs were re-measured at 30 min, 1 hour, 2 hours, 3 hours and 4 hours after instillation. Results were expressed as mean \pm SD of changes in IOP (mm Hg) from the basal T_0 levels measured just prior to the instillation of active test agent or vehicle. The significance of the data was determined as the difference from the T_0 value using Dunnett's t-test, as well as use of an unpaired Student's t-test for comparisons of changes in IOP between test substance and vehicle at matched time points.

Vehicles consisted of 0.5% aqueous peanut oil. Formulation of test agents in peanut oil was performed as follows: peanut oil formulations were prepared by dissolving 0.5%, 0.2%, 0.1%, 0.05%, 0.025% or 0.01% (wt./wt) of the test compound in peanut oil. Sonication was used to obtain complete dissolution of the compound.

Table 1 evaluates the effect of 0.5% timolol (free base equivalent) formulated in peanut oil and shows significant IOP lowering with timolol in the peanut oil vehicle. Tables 2 and 3 demonstrate significant IOP lowering with the administration of 0.1% paxilline and penitrm A, respectively (two known maxi-K channel blockers) formulated in peanut oil. Table 4 demonstrates significant IOP lowering with the administration of 0.2% Compound 1 formulated in peanut oil. Table 5 assesses the effects on IOP of 0.1% afletrem (a known maxi-K channel blocker) formulated in peanut oil.

Table 1.

Effect of Timolol Free Base (0.5%) in Peanut Oil on IOP in Dutch Belted Rabbits						
Parameter/	Time 0	30 min	60 min	120 min	180 min	240 min
Comparison	(mmHg)	(Δ mmHg)	(Δ mmHg)	(Δ mmHg)	(Δ mmHg)	(Δ mmHg)
Control Mean	21.04	-0.25	0.13	0.50	0	-0.13
(vehicle) STD	1.68	1.19	1.48	1.53	1.69	1.85
P vs Time 0		0.64	0.83	0.35	1.0	0.83
Treated Mean	21.00	-2.63	-3.46	-3.96	-4.21	-2.04
STD	1.93	2.18	2.19	1.97	1.91	1.60
P vs Control		0.0001	0.0001	0.0001	0.0004	0.0004
P vs Time 0		0.0003	0.0001	0.0001	0.0004	0.0005

n=24

Table 2.

Effect of Paxilline (0.1%) in Peanut Oil on IOP in Dutch Belted Rabbits

5	Parameter/	Time 0	30 min	60 min	120 min	180 min	240 min
	<u>Comparison(mmHg)</u>		<u>(ΔmmHg)</u>	<u>(ΔmmHg)</u>	<u>(ΔmmHg)</u>	<u>(ΔmmHg)</u>	<u>(ΔmmHg)</u>
	Control Mean	22.04	-0.42	-0.67	-1.17	0	-0.67
	(vehicle) STD	1.73	1.69	1.69	2.24	1.67	2.08
	P vs Time0		0.44	0.22	0.06	1.0	0.26
10	Treated Mean	22.21	-0.79	-2.67	-2.67	-1.71	-1.38
	STD	1.53	1.61	2.12	1.81	1.33	1.76
	P vs Control		0.44	0.0008	0.01	0.0003	0.21
	P vs Time 0		0.11	0.0001	0.0001	0.001	0.008

15 n=24

Table 3.

Effect of Penitrem A (0.1%) in Peanut Oil on IOP in Dutch Belted Rabbits

	Parameter/	Time 0	30 min	60 min	120 min	180 min	240 min
	<u>Comparison(mmHg)</u>		<u>(ΔmmHg)</u>	<u>(ΔmmHg)</u>	<u>(ΔmmHg)</u>	<u>(ΔmmHg)</u>	<u>(ΔmmHg)</u>
20	Control Mean	21.75	0.50	0.21	-0.88	-0.67	-0.46
	(vehicle) STD	1.51	0.98	1.18	2.09	2.01	1.89
	P vs Time0		0.24	0.64	0.14	0.28	0.35
	Treated Mean	21.75	-1.33	-2.08	-3.91	-2.96	-2.46
25	STD	1.51	1.88	1.77	1.67	1.90	1.82
	P vs Control		0.0002	0.0001	0.0001	0.0002	0.0005
	P vs Time 0		0.02	0.0002	0.0001	0.0001	0.0001

n=24

30 Table 4.

Effect of Compound 1 (0.2%) in Peanut Oil on IOP in Dutch Belted Rabbits

	Parameter/	Time 0	30 min	60 min	120 min	180 min	240 min
	<u>Comparison(mmHg)</u>		<u>(ΔmmHg)</u>	<u>(ΔmmHg)</u>	<u>(ΔmmHg)</u>	<u>(ΔmmHg)</u>	<u>(ΔmmHg)</u>
	Control Mean	20.50	0.17	0.50	-0.29	0.17	-0.13
35	(vehicle) STD	1.53	1.55	1.84	1.37	1.66	1.75

	P vs Time0	0.73	0.33	0.57	0.76	0.82	
	Treated Mean	20.50	-2.0	-2.58	-2.96	-2.42	-1.58
	STD	1.35	1.29	0.93	1.60	1.86	2.39
5	P vs Control	0.0001	0.0001	0.0001	0.0001	0.0001	0.02
	P vs Time 0	0.0002	0.0001	0.0001	0.0001	0.0001	0.01
	n=24						

10

Table 5.

Effect of Afletrem (0.1%) in Peanut Oil on IOP in Dutch Belted Rabbits

	Parameter/Time 0	30 min	60 min	120 min	180 min	240 min
	Comparison(mmHg)	(ΔmmHg)	(ΔmmHg)	(ΔmmHg)	(ΔmmHg)	(ΔmmHg)
15	Control Mean	21.83	0.17	0.88	0.04	0.63
	(vehicle)STD	1.52	1.17	1.51	1.37	1.38
	P vs Time0	0.68	0.07	0.93	0.17	0.36
20	Treated Mean	21.83	-1.54	-2.04	-2.54	-2.13
	STD	1.86	1.96	2.31	2.30	1.65
	P vs Control	0.0007	0.0001	0.0001	0.0001	0.008
	P vs Time 0	0.004	0.0004	0.0001	0.0002	0.02
n=24						

25 FUNCTIONAL ASSAYS

A. Maxi-K Channel

The identification of inhibitors of the Maxi-K channel is accomplished using Aurora Biosciences technology, and is based on the ability of expressed Maxi-K channels to set cellular resting potential after transient transfection of both α and β 1 subunits of the channel in TsA-201 cells. In the absence of inhibitors, cells display a hyperpolarized membrane potential, negative inside, close to E_K (-80 mV) which is a consequence of the activity of the Maxi-K channel. Blockade of the Maxi-K channel will cause cell depolarization. Changes in membrane potential can be determined with voltage-sensitive fluorescence resonance energy transfer (FRET) dye pairs that use two components, a donor coumarin (CC₂DMPE) and an acceptor oxanol

(DiSBAC₂(3)). Oxanol is a lipophilic anion and distributes across the membrane according to membrane potential. Under normal conditions, when the inside of the cell is negative with respect to the outside, oxanol is accumulated at the outer leaflet of the membrane and excitation of coumarin will cause FRET to occur. Conditions
5 that lead to membrane depolarization will cause the oxanol to redistribute to the inside of the cell, and, as a consequence, to a decrease in FRET. Thus, the ratio change (donor/acceptor) increases after membrane depolarization.

Transient transfection of the Maxi-K channel in TsA-201 cells was carried out as previously described (Hanner et al. (1998) J. Biol. Chem. 273, 16289-
10 16296) using FUGENE as the transfection reagent. Twenty-four hours after transfection, cells are collected in Ca²⁺-Mg²⁺-free Dulbecco's phosphate-buffered saline (D-PBS), subjected to centrifugation, plated onto 96-well poly-d-lysine coated plates at a density of 50,000 cells/well, and incubated overnight. The cells are then washed 1x with D-PBS, and loaded with 100 µl of 4 mM CC₂DMPE-0.02% pluronic-
15 127 in D-PBS. Cells are incubated at room temperature for 30 min in the dark. Afterwards, cells are washed 2x with D-PBS and loaded with 100 µl of 5 mM DiSBAC₂(3) in (mM): 140 NaCl, 0.1 KCl, 1 CaCl₂, 0.5 MgCl₂, 20 Hepes-Tris, pH 7.4, 10 glucose. Test compounds are diluted into this solution, and added at the same time. Cells are incubated at room temperature for 30 min in the dark.

20 Plates are loaded into a voltage/ion probe reader (VIPR) instrument, and the fluorescence emission of both CC₂DMPE and DiSBAC₂(3) are recorded for 10 sec. At this point, 100 µl of high-potassium solution (mM): 140 KCl, 1 CaCl₂, 0.5 MgCl₂, 20 Hepes-Tris, pH 7.4, 10 glucose are added and the fluorescence emission of both dyes recorded for an additional 10 sec. The ratio CC₂DMPE/DiSBAC₂(3),
25 before addition of high-potassium solution equals 1. In the absence of any inhibitor, the ratio after addition of high-potassium solution varies between 1.65-2.0. When the Maxi-K channel has been completely inhibited by either a known standard or test compound, this ratio remains at 1. It is possible, therefore, to titrate the activity of a Maxi-K channel inhibitor by monitoring the concentration-dependent change in the
30 fluorescence ratio.

The compounds of this invention were found to cause concentration-dependent inhibition of the fluorescence ratio with IC₅₀'s in the range of about 1nM to about 1 µM, more preferably from about 10 nM to about 200 nM.

B. Electrophysiological assays of compound effects on high-conductance calcium-activated potassium channels

Human non-pigmented ciliary epithelial cells

5 The activity of high-conductance calcium-activated potassium (maxi-K) channels in human non-pigmented ciliary epithelial cells was determined using electrophysiological methods. Currents through maxi-K channels were recorded in the inside-out configuration of the patch clamp technique, where the pipette solution faces the extracellular side of the channel and the bath solution faces the intracellular side. Excised patches contained one to about fifty maxi-K channels. Maxi-K channels were identified by their large single channel conductance (250-300 pS), and by sensitivity of channel gating to membrane potential and intracellular calcium concentration. Membrane currents were recorded using standard electrophysiological techniques. Glass pipettes (Garner 7052) were pulled in two stages with a Kopf puller 10 (model 750), and electrode resistance was 1-3 megohms when filled with saline. Membrane currents were recorded with EPC9 (HEKA Instruments) or Axopatch 1D (Axon Instruments) amplifiers, and digital conversion was done with ITC-16 interfaces (Instrutech Corp). Pipettes were filled with (mM); 150 KCl, 10 Hepes, 1 MgCl₂, 0.01 CaCl₂, 3.65 KOH, pH 7.20. The bath (intracellular) solution was 15 identical, except, in some cases, calcium was removed, 1 mM EGTA was added and 20 mM KCl was replaced with 20 mM KF to eliminate calcium to test for calcium sensitivity of channel gating. Drugs were applied to the intracellular side of the channel by bath perfusion.

 Human non-pigmented ciliary epithelial cells were grown in tissue 25 culture as described (Martin-Vasallo, P., Ghosh, S., and Coca-Prados, M., 1989, J. Cell. Physiol. 141, 243-252), and plated onto glass cover slips prior to use. High resistance seals (>1 Gohm) were formed between the pipette and cell surface, and inside out patches were excised. Maxi-K channels in the patch were identified by their gating properties; channel open probability increased in response to membrane 30 depolarization and elevated intracellular calcium. In patches used for pharmacological analysis, removing intracellular calcium eliminated voltage-gated currents. Maxi-K currents were measured after depolarizing voltage steps or ramps that caused channel opening.

 The compounds of this invention were applied to the intracellular side 35 of the channel in appropriate concentrations (0.001 to 10 μ M). The compounds

reduced channel open probability, and this effect was reversed upon washout of compounds from the experimental chamber. The IC₅₀ for block of maxi-K channels under these conditions for the compounds of this invention ranged from about 0.5 nM to about 300 nM.


5

WHAT IS CLAIMED IS:

1. An ophthalmic formulation for the treatment of ocular hypertension or glaucoma in a subject in need thereof comprising a potassium channel blocker in combination with a pharmaceutically acceptable peanut oil vehicle.


5

2. An ophthalmic formulation for the treatment of ocular hypertension or glaucoma in a subject in need thereof comprising 0.01 to 5% (wt/wt) of a potassium channel blocker of the structural formulas:



10

FORMULA I, or



FORMULA II

15

or a pharmaceutically acceptable salt, enantiomer, diastereomer or mixture thereof: wherein,

20 R and R^x independently represent C₁₋₆ alkyl, (CH₂)_naryl, (CH₂)_nheteroaryl, (CH₂)_n heterocycloalkyl, said alkyl, aryl or heteroaryl optionally substituted with 1-3 groups of R_Y;

Y represents -(CH₂)_nSCOR^z;

X represents CH₂, or O (in which m does not exist);

RY represents hydrogen, C₁₋₆ alkoxy, C₁₋₆ alkyl, CF₃, nitro, amino, cyano, C₁₋₆
5 alkylamino, or halogen and

R^Z represents C₁₋₆ alkoxy, or C₁₋₆ alkyl;

m represents 1-3;

10

n represents 0-3

R₁ represents hydrogen or C₁₋₆ alkyl;

15 R₂, R_{3a} and R_{3b} independently represent hydrogen, C₁₋₁₀ alkyl, C₃₋₁₀ cycloalkyl, C₄₋₁₀ heterocycloalkyl, C₄₋₁₀ heteroaryl, or C₆₋₁₀ aryl;

R₄ represents hydrogen, C₁₋₆ alkoxy, C₁₋₆ alkyl, CF₃, or halogen;

20 R₅ represents hydrogen, C₁₋₆ alkoxy, C₁₋₆ alkyl, CF₃, nitro, amino, cyano, C₁₋₆ alkylamino, or halogen;

R₆ represents hydrogen, halogen or C₁₋₆ alkyl; and


R⁷ represents H, halo, OH, NO₂, NH₂, CN, alkoxy, -COO-, alkoxycarbonyl,

25 haloalkyl, alkoxycarbonylalkyl, or alkylsulphonyl,
in combination with a pharmaceutically acceptable peanut oil vehicle.

3. The formulation of Claim 2 wherein the concentration of maxi-K channel blocker is 0.2 to 2%.


30

4. The formulation of claim 2 wherein the maxi-K channel blocker is a compound presented by formula I:



wherein:

- 5 R_2 and R_{3b} independently represent C_{1-6} alkyl or C_{3-10} cycloalkyl and all other variables are as originally described for the compounds of formula I.
5. A formulation according to claim 4 wherein R_1 is C_{1-6} alkyl, R_2 and R_{3b} independently are C_{1-6} alkyl or C_{3-10} cycloalkyl, R_4 is hydrogen, R_5 is C_{1-6} alkoxy, or C_{1-6} alkyl, R_{3a} is hydrogen and R_6 is halogen or C_{1-6} alkyl.
6. A formulation according to claim 5 wherein R_1 is C_{1-3} alkyl,
- 10 R_2 and R_{3b} independently are C_{1-4} alkyl or C_{5-10} cycloalkyl, R_4 is hydrogen, R_5 is C_{1-3} alkoxy, and R_6 is halogen.
7. The formulation of claim 2 wherein the maxi-K channel blocker is a compound presented by formula II:





15 FORMULA II

wherein

R and R^x independently are C_{1-6} alkyl, or $(CH_2)_n$ aryl, X is CH_2 , R^7 is H and Y is $-(CH_2)_nSCOR^z$ wherein $n=0$, and all other variables are as originally described for the compounds of formula II.

8. A formulation according to claim 2 wherein Y is –
(CH₂)_nSCORZ, wherein n=1-3, and all other variables are as originally described for
the compounds of formula II.
9. A formulation according to claim 2 wherein R is (CH₂)_n aryl,
5 R^x is C₁₋₆ alkyl, Y is (CH₂)_nSCORZ, X is CH₂ and m=1 for the compounds of
formula II.
10. A formulation according to claim 2 wherein R is (CH₂)_naryl,
R^x is C₁₋₆ alkyl, Y is (CH₂)_nSCORZ, X is CH₂ and m=2 for the compounds of
formula II.
11. A formulation according to claim 2 wherein R is C₁₋₆ alkyl, R^x
10 is (CH₂)_naryl, Y is (CH₂)_n SCORZ, X is CH₂ and m=2 for the compounds of formula
II.
12. A formulation according to claim 2 wherein R is (CH₂)_naryl,
R^x is (CH₂)_naryl, Y is (CH₂)_n SCORZ, X is CH₂ and m=2 for the compounds of
15 formula II.
13. A formulation according to claim 2 wherein the maxi-K
channel blocker is:





14. A formulation according to claim 2 which also contains 0.01 to 1% of a β -adrenergic antagonist.
15. A formulation according to claim 14 wherein the β -adrenergic antagonist is betaxolol, bufenolol, carteolol, levobunolol, metipranolol, timolol or a pharmaceutically acceptable salt thereof.
16. A formulation according to claim 15 wherein the β -adrenergic antagonist is timolol.

17. A formulation according to claim 2 which also contains 0.05 to 5% of a carbonic anhydrase inhibitor.

5 18. A formulation according to claim 17 wherein the carbonic anhydrase inhibitor is dorzolamide, brinzolamide or a pharmaceutically acceptable salt thereof.

10 19. A formulation according to claim 16 which also contains a carbonic anhydrase inhibitor.

20. A formulation according to claim 19 wherein the carbonic anhydrase inhibitor is dorzolamide or brinzolamide.

15 21. A formulation according to claim 2 which also contains 0.05 to 5% (wt/wt) of a prostaglandin.

20 22. A formulation according to claim 21 wherein the prostaglandin is latanoprost, rescula, S1033 or a hypotensive lipid derived from PGF2 α prostaglandins such as prostamide or a pharmaceutically acceptable salt thereof.

23. A formulation according to claim 1 which is in the form of an ocular insert.

25

BLANK PAGE

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
8 August 2002 (08.08.2002)

PCT

(10) International Publication Number
WO 02/060339 A3

(51) International Patent Classification⁷: **A61K 31/40**,
31/405

(21) International Application Number: PCT/US02/02011

(22) International Filing Date: 25 January 2002 (25.01.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/264,957 30 January 2001 (30.01.2001) US

(71) Applicant (*for all designated States except US*): **MERCK & CO., INC.** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(72) Inventor; and

(75) Inventor/Applicant (*for US only*): **STELMACH, Christine** [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(74) Common Representative: **AYLER, Sylvia, A. et al.**; Merck & Co., Inc., 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

(88) Date of publication of the international search report:
14 November 2002

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/060339 A3

(54) Title: OPTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION

(57) Abstract: This invention relates a formulation comprising potent potassium channel blockers or pharmaceutically acceptable salts thereof in combination with peanut oil for the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/02011

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A61K 81/40, 81/405

US CL : 514/412, 415

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 514/412, 415

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched
NONE

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

WEST

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5,573,758 A (ADORANTE ET AL) 12 November 1996 (12.11.96), see the entire document.	1-23



Further documents are listed in the continuation of Box C.



See patent family annex.

"A"	document defining the general state of the art which is not considered to be of particular relevance	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"E"	earlier document published on or after the international filing date	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"L"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"G"	document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

19 APRIL 2002

Date of mailing of the international search report

23 SEP 2002

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer:

D. Roberts for
Z. H. FAY

Telephone No. (703) 308-1235

Form PCT/ISA/210 (second sheet) (July 1998)*

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US02/02011

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all req
searchable national search report covers all
2. ☐ As all sear
of any add s Authority did not invite payment
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest☐
☐

The additional search fees were accompanied by the applicant's protest.

No protest accompanied the payment of additional search fees.

BLANK PAGE